Hansa Biopharma AB's total assets for Q4 2025 were kr1.17B, an increase of 57.44% from the previous quarter. SE:HNSA total liabilities were kr1.25B for the fiscal quarter, a -3.91% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.